Clinical Trials

25 enrolled

Multiple Myeloma

NCT02362035 2025-12-11

KEYNOTE145

161 enrolled 29 charts

Burkitt Lymphoma, Hodgkin Disease, Leukemia, Hairy Cell, Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell

NCT02356159 2025-09-30

Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation

LymphoidMyeloidOther hematologic neoplasmPlasma cell

34 enrolled 18 charts

Hodgkin Disease, Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes

NCT07102706 2025-08-05

Phase I Trial of GR1803 Injection in Patients With RRMM

76 enrolled

Multiple Myeloma

NCT03548207 2025-07-30

CARTITUDE-1

126 enrolled 36 charts 1 FDA

Multiple Myeloma

NCT01864018 2025-07-24

Ixazomib With Cyclophosphamide and Dexamethasone in Patients With Previously Untreated Symptomatic Multiple Myeloma or Light Chain Amyloidosis

87 enrolled 13 charts

Amyloidosis, Multiple Myeloma

NCT06055075 2025-07-14

A Study Evaluating Safety, Tolerability, and Clinical Activity of Forimtamig-Based Treatment Combinations in Participants With Relapsed or Refractory Multiple Myeloma

19 enrolled

Multiple Myeloma, Recurrence

NCT00112827 2025-06-06

Melphalan and Radiation Therapy Followed By Lenalidomide in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant for Stage I, Stage II, or Stage III Multiple Myeloma

54 enrolled 13 charts

Smoldering Multiple Myeloma, Multiple Myeloma

NCT04083534 2025-05-30

First In Human (FIH) Study of REGN5459 in Adult Patients With Relapsed or Refractory Multiple Myeloma (MM)

43 enrolled

Multiple Myeloma

NCT03417284 2025-05-01

Melphalan Hydrochloride in Treating Participants With Newly-Diagnosed Multiple Myeloma Undergoing Donor Stem Cell Transplantation

62 enrolled 10 charts

Multiple Myeloma

NCT02649790 2025-03-19

Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications

GastrointestinalMyeloidOther hematologic neoplasmPlasma cell

277 enrolled

Multiple Myeloma, Myelodysplastic Syndromes, Colorectal Neoplasms, Leukemia, Myeloid, Acute

NCT03544281 2025-03-18

DREAMM 6

153 enrolled 91 charts

Multiple Myeloma

NCT03732703 2025-02-14

MyDRUG

103 enrolled

Multiple Myeloma

NCT03773107 2025-01-13

LCI-HEM-MYE-CRD-004 (MMRC-073 CARJAK): Study of CRD for Carfilzomib-Refractory Multiple Myeloma

12 enrolled 19 charts

Multiple Myeloma, Neoplasms, Plasma Cell

NCT03997968 2024-12-24

A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors

BreastGastrointestinalGynecologicHead & NeckLymphoidPlasma cellSarcomaThoracic

169 enrolled

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Head and Neck Neoplasms, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Multiple Myeloma, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Sarcoma, Lymphoma, Mantle-Cell, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT01755975 2024-11-07

Romidepsin in Combination With Lenalidomide in Adults With Relapsed or Refractory Lymphomas and Myeloma

49 enrolled 15 charts

LymphoidPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma

NCT01827137 2024-09-19

WT1 Vaccine Treatment of Patients With Multiple Myeloma After Autologous Stem Cell Transplantation

20 enrolled 9 charts

GenitourinaryPlasma cell

Multiple Myeloma, Wilms Tumor

NCT02633059 2024-09-19

Idasanutlin, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma

33 enrolled 26 charts

Chromosome 17 deletion, Multiple Myeloma

NCT03267888 2024-09-04

Pembrolizumab and Radiation Therapy in Patients With Relapsed or Refractory Multiple Myeloma

25 enrolled 11 charts

Multiple Myeloma

NCT01183949 2024-08-02

Effect of AT7519M Alone and AT7519M Plus Bortezomib in Patients With Previously Treated Multiple Myeloma

18 enrolled

LymphoidPlasma cell

Blood Protein Disorders, Hematologic Diseases, Hemorrhagic Disorders, Immune System Diseases, Immunoproliferative Disorders, Lymphoproliferative Disorders, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Paraproteinemias, Hemostatic Disorders, Neoplasms, Plasma Cell

NCT03194867 2024-06-14

Isatuximab in Combination With Cemiplimab in Relapsed/Refractory Multiple Myeloma (RRMM) Patients

109 enrolled 27 charts

Multiple Myeloma

NCT01063907 2024-04-25

A Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma

95 enrolled 13 charts

Bronchiolitis Obliterans Syndrome, Blood Protein Disorders, Hematologic Diseases, Immune System Diseases, Immunoproliferative Disorders, Leukemia, Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma, Paraproteinemias, Leukemia, B-Cell, Neoplasms, Plasma Cell

NCT03848845 2024-04-09

DREAMM 4

41 enrolled 57 charts

Multiple Myeloma

NCT02119468 2024-03-15

Ixazomib Plus Pomalidomide and Dexamethasone in Treating Patients With Relapsed or Relapsed/Refractory Multiple Myeloma

32 enrolled 15 charts

Multiple Myeloma

NCT02206425 2023-10-31

Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients

45 enrolled

Multiple Myeloma, Recurrence

NCT02685826 2023-10-06

A Study of Durvalumab in Combination With Lenalidomide With and Without Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma

56 enrolled 38 charts

Multiple Myeloma

NCT04445701 2023-08-22

Study of AO-176 as Monotherapy and in Combination With Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma

10 enrolled

Multiple Myeloma

NCT02204241 2023-07-03

CCD

36 enrolled

Disease, Multiple Myeloma

NCT01348919 2023-06-28

Delanzomib (CEP-18770) in Combination With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma

11 enrolled 15 charts

Multiple Myeloma, Neoplasms

NCT00566098 2023-05-26

Activated White Blood Cells With ASCT for Newly Diagnosed Multiple Myeloma

26 enrolled 13 charts

Multiple Myeloma, Neoplasms, Plasma Cell

NCT02751255 2023-04-28

DARA/ATRA

60 enrolled

Multiple Myeloma

NCT01794520 2023-04-10

Study Evaluating ABT-199 in Participants With Relapsed or Refractory Multiple Myeloma

117 enrolled 29 charts

Multiple Myeloma

NCT01040026 2023-04-04

Expanded Natural Killer (NK) Cells for Multiple Myeloma Study

10 enrolled

Multiple Myeloma

NCT03312530 2023-02-28

A Study of Cobimetinib Administered as Single Agent and in Combination With Venetoclax, With or Without Atezolizumab, in Participants With Relapsed and Refractory Multiple Myeloma

49 enrolled 24 charts

Multiple Myeloma

NCT03439280 2023-02-24

A Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-079 Administered Subcutaneously as a Single Agent in Participants With Relapsed/Refractory (r/r) Multiple Myeloma (MM)

50 enrolled 26 charts

Multiple Myeloma, Recurrence

NCT02186834 2023-01-04

Selinexor (KPT-330) and Liposomal Doxorubicin For Relapsed and Refractory Multiple Myeloma

28 enrolled 10 charts

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

NCT01242267 2023-01-03

Thal/Mel/Vel

29 enrolled 13 charts

Multiple Myeloma

NCT01177397 2022-12-13

Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma

CNSGastrointestinalLymphoidPlasma cellThoracic

226 enrolled 42 charts

Carcinoma, Non-Small-Cell Lung, Glioblastoma, Carcinoma, Hepatocellular, Multiple Myeloma, Lymphoma, Large B-Cell, Diffuse

NCT01947140 2022-11-23

PDX+Romi

DermatologicLymphoidOther hematologic neoplasmPlasma cell

57 enrolled

Burkitt Lymphoma, Hodgkin Disease, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT01677858 2022-09-23

CHAMPION 1

116 enrolled 28 charts

Multiple Myeloma

NCT00784823 2022-08-11

Mel-Vel

32 enrolled 8 charts

Multiple Myeloma

NCT02384083 2022-07-27

Filanesib (ARRY-520) in Combination With Pomalidomide and Dexamethasone for Relapsed/Refractory (R/R) Multiple Myeloma (MM) Patients

47 enrolled

Multiple Myeloma

NCT01502085 2022-01-21

RZD

25 enrolled 5 charts

Multiple Myeloma

NCT02145403 2022-01-03

Phase 1/2 Study of Carfilzomib for the Prevention of Relapse and GVHD in Allo-HCT for Hematologic Malignancies

53 enrolled 17 charts

Graft vs Host Disease, Leukemia, Lymphoma, Multiple Myeloma, Recurrence, Hematologic Neoplasms

NCT01421186 2021-11-16

A Phase 1/2a Study of Human Anti-CD 38 Antibody MOR03087 (MOR202) in Relapsed/Refractory Multiple Myeloma

91 enrolled 19 charts

Multiple Myeloma

NCT00421525 2021-08-16

Phase I/II Study of hLL1 in Multiple Myeloma

25 enrolled

Multiple Myeloma, Plasmacytoma

NCT02265731 2021-08-02

Study Evaluating Venetoclax in Subjects With Hematological Malignancies

38 enrolled

Lymphatic Diseases, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute

NCT03665155 2021-07-30

First-in- Human Imaging of Multiple Myeloma Using 89Zr-DFO-daratumumab, a CD38-targeting Monoclonal Antibody

11 enrolled 11 charts

Multiple Myeloma

NCT00708292 2020-12-17

A Phase I-Ib/II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 Alone and in Combination With Bortezomib, With or Without Dexamethasone, in Patients With Relapsed or Refractory Multiple Myeloma.

29 enrolled